NCT01641042 - Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 10, 2012

Primary Completion Date

October 10, 2014

Study Completion Date

March 3, 2015

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL

Meningococcal vaccine GSK134612

2 doses of the vaccine administered intramuscularly in the anterolateral thigh muscle of the non-dominant leg for subjects aged 12 months to 2 years and in the deltoid of the non-dominant arm for older subjects.

Trial Locations (16)

27704

GSK Investigational Site, Durham

27705

GSK Investigational Site, Durham

94015

GSK Investigational Site, Daly City

94063

GSK Investigational Site, Redwood City

94509

GSK Investigational Site, Antioch

94538

GSK Investigational Site, Fremont

94545

GSK Investigational Site, Hayward

94589

GSK Investigational Site, Vallejo

94611

GSK Investigational Site, Oakland

95051

GSK Investigational Site, Santa Clara

95403

GSK Investigational Site, Santa Rosa

95661

GSK Investigational Site, Roseville

95815

GSK Investigational Site, Sacramento

95823

GSK Investigational Site, Sacramento

613 00

GSK Investigational Site, Brno

500 02

GSK Investigational Site, Hradec Králové